Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories

  • FDA De Novo authorization for the cobas® pro i 601 platform with Ionify® Gabapentin assay expands Roche's mass spectrometry menu into therapeutic drug monitoring. 
  • Designed to simplify traditionally complex testing, the solution brings the analytical capabilities of mass spectrometry together with an automated, standardized laboratory workflow.
  • Roche will utilize an FDA-authorized Predetermined Change Control Plan (PCCP) to accelerate future clinical mass spectrometry menu expansion while maintaining rigorous safety and quality standards.

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the cobas® pro i 601 platform with the Ionify® Gabapentin assay, components of its cobas® Mass Spec solution. Designed to bring advanced mass spectrometry testing into routine clinical laboratories, the solution combines the analytical capabilities of mass spectrometry with an automated, standardized workflow expanding Roche's diagnostic menu into therapeutic drug monitoring.

Roche logo

Mass spectrometry is widely used for clinical applications requiring highly sensitive and specific measurement, but traditional methods often involve specialized personnel and complex manual workflows. Roche is pioneering the transition of mass spectrometry from specialized reference facilities to the core laboratory, redefining complex testing into an accessible, standardized solution for routine clinical practice. 

Authorized through the De Novo pathway, the Ionify® Gabapentin assay adds a therapeutic drug monitoring application to a U.S. menu that includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone. Roche continues to develop additional clinical mass spectrometry assays to broaden the menu over time. Demonstrating an innovative, collaborative approach with the FDA, Roche will leverage a Predetermined Change Control Plan (PCCP), to drive and accelerate future clinical mass spectrometry menu expansion while still maintaining rigorous safety and quality standards. The authorized PCCP includes the expansion of up to 22 Ionify® assays on the cobas® pro i 601 platform as PCCP requirements are met. These additional assays are not yet available and will be introduced in the future as applicable requirements are met.

"Some of the best diagnostic technologies are often very complex and, in the end, don't actually reach patients," said Dan Malarek, President and CEO of Roche Diagnostics North America. "Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories. By automating and standardizing this technology, we're helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results."

About the cobas® Mass Spec solution
Mass spectrometry is widely regarded as a gold-standard analytical method for certain clinical applications, including steroid hormone measurement, vitamin D testing and therapeutic drug monitoring. The cobas® Mass Spec solution combines the high specificity, sensitivity and accuracy of mass spectrometry with an automated, standardized workflow designed to make this traditionally complex technology more accessible to routine clinical laboratories.

In July 2025, the cobas® Mass Spec solution received the Best New Clinical Diagnostics Instrumentation of 2024 award in the Scientists' Choice Awards® 2025, recognizing innovation in clinical laboratory technology.

For more information about cobas® Mass Spec solution, please visit go.roche.com/ClinicalMassSpec.

About Roche 
Roche is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland, in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

For Further Information

Roche Diagnostics U.S. Media Relations
us.mediarelations@roche.com

Amy Lynn
+1-317-750-7811
amy.lynn@roche.com 

Jen Dial
+1-463-867-0232
jen.dial@roche.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/roche-receives-fda-de-novo-authorization-for-cobas-pro-i-601-platform-with-ionify-gabapentin-assay-advancing-automated-mass-spectrometry-for-routine-clinical-laboratories-302939987.html

SOURCE Roche Diagnostics

News Provided by PR Newswire via QuoteMedia

RHHBY
The Conversation (0)
Five-year Data for Genentech's Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy  Achieved or Maintained the Ability to Sit, Stand or Walk

Five-year Data for Genentech's Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy Achieved or Maintained the Ability to Sit, Stand or Walk

- After 5 years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past 2 years of age - - 96% of Evrysdi-treated children could swallow, 80% could feed without a feeding tube and 59% could sit without support for at least 30... Keep Reading...
FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options – – Additional analyses of INAVO120 will be presented in an oral abstract session at the 2024 American Society of Clinical Oncology Annual Meeting – – The... Keep Reading...
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwide Upcoming launches of the new cobas ® c703 & ISE neo units and cobas ® Mass Spec solution are testament to the... Keep Reading...
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting – – Approximately 40% of people with HR-positive breast cancer have a PIK3CA mutation... Keep Reading...
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p – At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight... Keep Reading...

Interactive Chart

Latest Press Releases

Related News